Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and AustraliaBusiness Wire • 11/05/20
Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Business Wire • 11/02/20
Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020Business Wire • 10/26/20
Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United StatesPRNewsWire • 10/15/20
Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access ProgramBusiness Wire • 09/01/20
Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020Business Wire • 08/29/20
Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth ConferenceBusiness Wire • 08/07/20
Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program UpdatesBusiness Wire • 08/06/20
Mirum Pharmaceuticals: Undervalued Rare Disease Player With Clear Path To MarketSeeking Alpha • 04/22/20
Mirum Pharma's Lead Asset Has $450M Sales Opportunity, Raymond James Says In Bullish InitiationBenzinga • 08/12/19